The reduced clearance observed for ESRD patients in the current study (58% of that for healthy individuals) is in agreement with other studies which have demonstrated a reduction in the metabolic clearance rate (MCR) of GH of about 50% for patients with chronic renal failure, and commensurate with a GH plasma half-life double that of healthy controls.23–25 GH appears to be eliminated in humans by a biocompartmental model,25,33 with unbound GH in a central compartment and GHBPs and bound GH in a peripheral compartment. The gene discussed is GH1; the disease is chronic kidney disease.